TSA Clarifies Medical Cannabis Airport Policy: 'No Changes' Despite May 2026 Headlines

The Transportation Security Administration has taken the unusual step of publicly clarifying that its TSA medical cannabis policy "has not changed" — even after the federal government's historic move to reschedule medical marijuana to Schedule III. The agency's May 21, 2026 statement came as travelers, dispensary staff, and patient advocates circulated viral social posts suggesting that medical patients could now fly freely with cannabis. They cannot, the TSA said.

For patients planning summer travel, the clarification matters. Medical marijuana, even when legally obtained under a qualifying state-issued license and now formally recognized at the federal level under Schedule III, is still subject to a screening framework designed before rescheduling — one that has not been updated to mirror the new federal classification. Until the TSA publicly amends its written guidance, the agency's longstanding default applies: marijuana, including most CBD products that exceed 0.3% THC, "remains illegal under federal law" for purposes of airport screening.

What the TSA Actually Said

In a statement first reported by Marijuana Moment on May 21, 2026, the TSA confirmed that "screening procedures have not changed" in the wake of the Justice Department's April 23, 2026 final rule placing FDA-approved marijuana products and state-licensed medical cannabis on Schedule III. The agency emphasized that its officers do not search travelers for marijuana, but if a controlled substance is discovered during routine carry-on or checked-bag screening, "TSA officers are required to refer the matter to law enforcement."

Whether the matter escalates depends on the local jurisdiction. At LAX, SFO, Denver International, Las Vegas (Harry Reid International), and Massport-managed Boston Logan — all in states with legal adult-use cannabis — local police generally decline to act on possession quantities consistent with personal use. At Atlanta Hartsfield-Jackson, Dallas-Fort Worth, Nashville, Memphis, and most airports in states without medical cannabis programs, the calculus is very different. The Schedule III rescheduling did not preempt state criminal codes, and it did not extinguish the gray area that medical patients have navigated for years.

What Schedule III Actually Changed — and What It Didn't

Schedule III is not the same as legalization. The April 23 DOJ final rule reclassified medical cannabis from Schedule I to Schedule III, a category that includes substances with accepted medical use and lower abuse potential than Schedule I or II compounds. The practical effects of that change are real but narrow: medical cannabis businesses can now claim federal income tax deductions previously denied under IRC Section 280E; FDA-approved cannabis-derived medications and state-licensed medical cannabis operations are eligible for expedited DEA registration; and research barriers begin to ease.

What Schedule III did not do is legalize cannabis for recreational use, create a federal medical marijuana program, or authorize interstate transport. It also did not change the rules at airport security checkpoints. The TSA's mission, the agency reiterated, is "to prevent threats to aviation security." Drug enforcement, the statement said, is "not a TSA priority" — but TSA officers are still required to refer discoveries of controlled substances to law enforcement.

The Schedule III move means medical marijuana now sits in the same regulatory tier as Tylenol with codeine, ketamine, and testosterone. None of those substances can be brought through TSA checkpoints without a valid prescription label that matches federal pharmacy standards — and state-issued medical marijuana recommendations do not yet meet that bar. The DEA's rule explicitly contemplates this gap: it created a registration pathway for state-licensed dispensaries, but until those dispensaries are federally registered and their product labeling meets federal standards, patient cards remain outside the federal prescription framework.

What Has Changed for Travelers

Two practical changes flow from the rescheduling and are worth flagging for cannabis-using travelers, even if the TSA's checkpoint posture is unchanged.

First, FDA-approved cannabis-derived medications — most notably Epidiolex, the FDA-approved CBD treatment for certain seizure disorders, and Marinol (dronabinol) — have always been permitted at TSA checkpoints in clearly labeled prescription containers. Schedule III formalizes that pathway and may eventually expand it as more FDA-approved cannabis medications enter the market, including Vertanical's VER-01, which received FDA Breakthrough Therapy designation earlier this year.

Second, hemp-derived CBD products containing less than 0.3% delta-9 THC remain permitted by TSA policy. That has been federal policy since the 2018 Farm Bill, and the TSA's May 2026 statement reaffirmed it. The November 12, 2026 federal hemp ban — which narrows hemp's definition to a 0.4-milligram total THC cap per container — has not yet taken effect, but travelers should expect another round of TSA clarifications when it does.

What the Statement Won't Help With

The TSA's clarification doesn't resolve the deeper jurisdictional puzzle that medical patients face when flying interstate. A Florida medical cannabis patient flying from Miami to Tampa can technically possess their products under state law, but if their flight is rerouted to Atlanta — where Georgia's medical program is narrower — the legal landscape changes at touchdown. The TSA's policy doesn't speak to that question. Neither does Schedule III.

For multi-state flights or international itineraries, the calculus is even riskier. International travel with any quantity of cannabis remains a federal crime in most destinations, and travelers have faced significant consequences abroad — most prominently in countries where cannabis possession carries lengthy prison sentences. The Bali arrest cases from 2026 underscored how dangerous casual assumptions about cannabis can be once a plane crosses a border.

What Patients Should Do

For medical cannabis patients who need to fly in 2026, the practical guidance has not changed from prior years, despite the headlines:

The safest approach remains shipping nothing and traveling with nothing. Most medical patients can identify a licensed dispensary at their destination state — Florida has 600-plus dispensaries, California has more than 1,200 — and acquire products legally on arrival. For patients with rare conditions or who use specific titrated formulations, working with a destination-state physician to obtain a temporary reciprocity card may be possible, depending on the state.

For patients who choose to carry medical cannabis through a TSA checkpoint, the empirical reality is that small quantities of properly packaged medical products are rarely confiscated and even more rarely referred to law enforcement in legal-cannabis states. But "rare" is not "never," and the legal consequences of an unfavorable referral can be severe — particularly for federal employees, those with security clearances, immigrants and visa holders, and patients with custody considerations or pending court matters.

What's Next

The TSA's clarification is unlikely to be its last word. The Justice Department's expedited rescheduling hearings, scheduled to begin June 29, 2026, are expected to address some of the practical questions that Schedule III leaves open — including transport across federal jurisdictions and the relationship between state-issued recommendations and federal prescription standards. If the rescheduling proceeds to a full Schedule III placement (covering all marijuana, not just state-licensed medical cannabis), the TSA would almost certainly issue revised checkpoint guidance.

Until then, the agency's message is straightforward: nothing has changed at the checkpoint. Patients should plan accordingly.

Key Takeaways

• The TSA confirmed on May 21, 2026 that its medical cannabis screening policy has not changed despite federal Schedule III rescheduling.
• TSA officers do not search for cannabis, but are required to refer discovered controlled substances to local law enforcement.
• FDA-approved cannabis medications (Epidiolex, Marinol) remain permitted; state-issued medical marijuana recommendations do not yet qualify as federal prescriptions.
• Hemp-derived CBD with less than 0.3% delta-9 THC remains permitted under TSA policy.
• The June 29, 2026 DEA hearings may produce further guidance, but until then, travelers should plan as if Schedule III made no difference at the checkpoint.

Explore cannabis news, find dispensaries, and join the community at Budpedia.